GlassScriptPhysician profile
Robert L Salant
NPI 1710901855
$5,909.68
in general payments reported to CMS, 2019-2025
31 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $949 · 2020: $508 · 2021: $284 · 2022: $581 · 2023: $1,218 · 2024: $1,192 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,430 · Food and Beverage: $1,209 · Honoraria: $950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,430.00 |
| Food and Beverage | $1,208.55 |
| Honoraria | $950.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $983.97 | 2022-2024 | Trelstar |
| Astellas Pharma US INC | $731.56 | 2019-2024 | Myrbetriq |
| Allergan, INC. | $632.39 | 2019-2021 | |
| Tersera Therapeutics LLC | $542.00 | 2023 | |
| Becton, Dickinson and Company | $488.00 | 2025 | |
| Cepheid | $407.00 | 2020 | |
| Dr.Reddy'S Laboratories,INC. | $400.00 | 2025 | |
| Cook Incorporated | $250.00 | 2023 | |
| Olympus America INC. | $226.96 | 2024-2025 | Itind System |
| Abbvie INC. | $201.67 | 2022-2025 | |
| Janssen Biotech, INC. | $133.40 | 2019-2022 | |
| Pfizer INC. | $110.18 | 2019-2025 | |
| Comsort, INC | $100.00 | 2019 | |
| Myriad Genetic Laboratories, INC. | $80.11 | 2022-2024 | Prolaris |
| Rochester Medical Corporation | $79.61 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $76.25 | 2022 | |
| Dendreon Pharmaceuticals LLC | $68.50 | 2024 | Provenge |
| Progenics Pharmaceuticals, INC. | $65.64 | 2022-2023 | Pylarify |
| Merck Sharp & Dohme LLC | $44.84 | 2022-2023 | Lynparza, Keytruda, Welireg |
| C. R. Bard, INC. & Subsidiaries | $44.44 | 2019 | |
| Acerus Pharmaceuticals Corporation | $31.99 | 2022 | |
| Laborie Medical Technologies Corp. | $26.32 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Teleflex LLC | $24.63 | 2023 | Urolift |
| Immunitybio, INC. | $23.92 | 2024 | |
| Boston Scientific Corporation | $23.77 | 2022 | |
| Medtronic, INC. | $22.64 | 2024 | Interstim |
| Sumitomo Pharma America, INC. | $21.83 | 2024 | Gemtesa |
| 180 Medical, INC. | $19.80 | 2023 | Gentlecath |
| Axonics, INC. | $17.01 | 2024 | Bulkamid |
| Tolmar, INC. | $16.68 | 2024 | |
| Coloplast Corp | $14.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Salant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.